The Cell2Cure core technology has been granted patent rights in Australia

As of the 24th of March 2022, the patent secures Cell2Cure’s technological concept for industrial production, upscaling, and distribution of allogeneic adipose-derived mesenchymal stromal cell (ASC) products in Australia (Patent number: 2016342387).

The patent “STEM CELL THERAPY BASED ON ADIPOSE-DERIVED STEM CELLS” has previously been granted in Europe (19 European PCT countries) year 2020: Publication number EP3365432B1. Priority: October 2016.

Applications are still pending in Canada, China, Hong Kong, Japan, The Republic of Korea and in USA.

We look forward to further strengthening of our intellectual property.